TheEdgeResearch
Home / Stocks / DBVT

DBV Technologies S.A. (DBVT)

NASDAQ Healthcare Biotechnology
$9.02 ▼ -4.25%
Market Cap
$215.8M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.21
52-Wk Range
8.63-26.19
CEO
Daniel Tassé
Country
FR
Currency
USD

DBV Technologies S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Châtillon, FR. The stock last traded at $9.02, down 4.25% on the session, giving a market capitalisation of $215.8M. On trailing twelve-month figures it carries a trailing P/E of -3.03, a net margin of -3631.5%. Its beta of -0.21 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-3.03
Price / Sales
99.69
Price / Book
5.61
EV / EBITDA
-2.01
Gross margin
-110.7%
Operating margin
-3687.1%
Net margin
-3631.5%
Return on equity
—
Debt / equity
0.05
Current ratio
3.24
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
125
IPO date
2014-10-22
Headquarters
Châtillon, FR
About DBV Technologies S.A.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.

Comparable companies

DBV Technologies S.A. is most often compared with the following Healthcare names:

ALTAMRNANNXANROCLLSENGNKRROLBRXLRMRLXEO
More research on DBVT
DBVT technical analysis DBVT TheEdge Score Compare against peers
Open full interactive analysis & DCF →